Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.

A highly significant effect of infliximab treatment (5 mg/kg body weight given at weeks 0, 2 and 6), with the primary outcome parameter of a 50% improvement of disease activity (BASDAI), was achieved in the treated group in comparison with the placebo group.

also in 132,142 other papers

Although there is a small trend towards a higher incidence of infusion reactions in patients who are positive for these antibodies, there is no indication to add methotrexate to infliximab to prevent infusion reactions.

also in 722 other papers